Senate approves Jane Henney to lead FDA
The U.S. Senate heeded the recommendation of the Senate Labor and Human Resources Committee and voted to confirm Jane Henney, M.D., as the commissioner of the Food and Drug Administration.
WASHINGTON - The U.S. Senate heeded the recommendation of the Senate Labor and Human Resources Committee and voted to confirm Jane Henney, M.D., as the commissioner of the Food and Drug Administration.
"The discussions I have had with many members of the Senate over the past several weeks have reaffirmed my belief that the FDA serves as a non-partisan arbiter of public policy, with decisions that are grounded in science and law," Henney said.
"As I have made clear in prior statements, my priority as commissioner will be to implement the FDA Modernization Act and to strengthen the agency's scientific base to ensure the best science guides the critical decisions that need to be made," Henney said.
Secretary Shalala said of Henney: "Jane Henney is a seasoned professional who brings substantial management skills and a depth of experience to the agency. The FDA safeguards food and drugs from the factory to the store shelf to every medicine cabinet and kitchen cupboard in America. Dr. Henney has the judgment to carry out that vital responsibility in a changing health marketplace, and I know that she will forge new and productive relationships with consumers and the industry." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
